In line with the reduction of liver steatosis, caspase-3 activity was decreased in liver tissues from anti-TNFR1-treated compared to control-Ab-treated NAFLD mice (Fig. 2a). Here, TNFRSF1A is linked to metabolic dysfunction-associated steatotic liver disease.